Chemical and Drug Induced Liver Injury
-
Subject Areas on Research
-
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.
-
A novel mouse model of depletion of stellate cells clarifies their role in ischemia/reperfusion- and endotoxin-induced acute liver injury.
-
A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development.
-
A pre-marketing ALT signal predicts post-marketing liver safety.
-
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
-
A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis.
-
A20 protects mice from lethal liver ischemia/reperfusion injury by increasing peroxisome proliferator-activated receptor-alpha expression.
-
Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo.
-
Absence of biochemical evidence for renal and hepatic dysfunction after 8 hours of 1.25 minimum alveolar concentration sevoflurane anesthesia in volunteers.
-
Acetaminophen and hepatic dysfunction in infectious mononucleosis.
-
Acetaminophen and liver disease.
-
Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series.
-
Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database.
-
Aging of the Liver: What This Means for Patients with HIV.
-
Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles.
-
Amiodarone hepatotoxicity simulating alcoholic liver disease.
-
Amoxicillin-Clavulanate-Induced Liver Injury.
-
An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data.
-
Anchoring hepatic gene expression with development of fibrosis and neoplasia in a toxicant-induced fish model of liver injury.
-
Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drug-induced Liver Injury in American Children.
-
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
-
Association of age-dependent liver injury and fibrosis with immune cell populations.
-
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
-
Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury.
-
Benzyl Alcohol: A novel treatment for acetaminophen overdose?
-
Benzyl alcohol protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes but causes mitochondrial dysfunction and cell death at higher doses.
-
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.
-
Catechins in dietary supplements and hepatotoxicity.
-
Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data.
-
Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases.
-
Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
-
Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.
-
Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.
-
Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™.
-
Complications of human immunodeficiency virus therapy.
-
Critical review of resveratrol in xenobiotic-induced hepatotoxicity.
-
Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.
-
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
-
Death and liver transplantation within 2 years of onset of drug-induced liver injury.
-
Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
-
Development and Validation of a Model Consisting of Comorbidity Burden to Calculate Risk of Death Within 6 Months for Patients With Suspected Drug-Induced Liver Injury.
-
Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells.
-
Diagnostic criteria for degenerative, inflammatory, proliferative nonneoplastic and neoplastic liver lesions in medaka (Oryzias latipes): consensus of a National Toxicology Program Pathology Working Group.
-
Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity.
-
Differential susceptibility to acetaminophen-induced liver injury in sub-strains of C57BL/6 mice: 6N versus 6J.
-
Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database.
-
Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach.
-
Drug rechallenge following drug-induced liver injury.
-
Drug-Induced Liver Injury.
-
Drug-induced liver injury.
-
Drug-induced liver injury: Interactions between drug properties and host factors.
-
Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
-
Dual Role of Epidermal Growth Factor Receptor in Liver Injury and Regeneration after Acetaminophen Overdose in Mice.
-
Editor's Highlight: Metformin Protects Against Acetaminophen Hepatotoxicity by Attenuation of Mitochondrial Oxidant Stress and Dysfunction.
-
Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
-
Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
-
Expanding our toolkit to better identify drug-induced liver injury in electronic medical records.
-
Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes).
-
Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury.
-
Fatal hepatic necrosis following imatinib mesylate therapy.
-
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
-
Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury.
-
Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury.
-
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
-
HLA-B*35:01 and Green Tea-Induced Liver Injury.
-
Hepatic accumulation of Hedgehog-reactive progenitors increases with severity of fatty liver damage in mice.
-
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.
-
Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis.
-
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
-
Identification and Characterization of Fenofibrate-Induced Liver Injury.
-
Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.
-
Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury.
-
Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP.
-
Increased hepatic oxygenation following ethanol administration in the baboon.
-
Induction of mitochondrial biogenesis protects against acetaminophen hepatotoxicity.
-
Inhibition of p53 Sulfoconjugation Prevents Oxidative Hepatotoxicity and Acute Liver Failure.
-
Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury.
-
L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury.
-
Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.
-
Liuweiwuling tablets protect against acetaminophen hepatotoxicity: What is the protective mechanism?
-
Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature.
-
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network.
-
Liver injury from nonsteroidal anti-inflammatory drugs in the United States.
-
Long-term mutagenicity studies with chloroform and dimethylnitrosamine in female lacI transgenic B6C3F1 mice.
-
Lower susceptibility of female mice to acetaminophen hepatotoxicity: Role of mitochondrial glutathione, oxidant stress and c-jun N-terminal kinase.
-
Magnetic resonance microscopy and histopathology: comparative approach of bromobenzene-induced hepatotoxicity in the rat.
-
Methylphenidate-induced autoimmune hepatitis.
-
Mining hidden knowledge for drug safety assessment: topic modeling of LiverTox as a case study.
-
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.
-
Mito-tempo protects against acute liver injury but induces limited secondary apoptosis during the late phase of acetaminophen hepatotoxicity.
-
Mitochondria-targeted antioxidant Mito-Tempo protects against acetaminophen hepatotoxicity.
-
Mitochondrial acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice.
-
Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review.
-
Mitochondrial protein adduct and superoxide generation are prerequisites for early activation of c-jun N-terminal kinase within the cytosol after an acetaminophen overdose in mice.
-
Mitochondrial protein adducts formation and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP)-induced hepatotoxicity in primary human hepatocytes.
-
Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
-
Monitoring liver safety in drug development: the GSK experience.
-
Nephrotoxicity and hepatotoxicity induced by inhaled bromodichloromethane in wild-type and p53-heterozygous mice.
-
Non-genetic risk factors and predicting efficacy for docetaxel--drug-induced liver injury among metastatic breast cancer patients.
-
Non-parenchymal cell responses in paracetamol (acetaminophen)-induced liver injury.
-
Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
-
Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and therapeutic potential.
-
Pathophysiological significance of c-jun N-terminal kinase in acetaminophen hepatotoxicity.
-
Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.
-
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
-
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
-
Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.
-
Pharmacovigilance and safety aspects of sevoflurane.
-
Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid "pulse therapy".
-
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
-
Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.
-
Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance.
-
Redefining IL11 as a regeneration-limiting hepatotoxin and therapeutic target in acetaminophen-induced liver injury.
-
Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.
-
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN).
-
Removal of acetaminophen protein adducts by autophagy protects against acetaminophen-induced liver injury in mice.
-
Resveratrol prevents protein nitration and release of endonucleases from mitochondria during acetaminophen hepatotoxicity.
-
Reversible nefazodone-induced liver failure.
-
Safety considerations with niacin therapy.
-
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
-
Sclerosing Cholangitis-Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury.
-
Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors.
-
Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study.
-
Significant Medical Comorbidities Are Associated With Lower Causality Scores in Patients Presenting With Suspected Drug-Induced Liver Injury.
-
Some effects of imidocarb in goats.
-
Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients.
-
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.
-
Statin safety: an assessment using an administrative claims database.
-
Telithromycin.
-
Tetracycline-induced bile duct paucity and prolonged cholestasis.
-
The gap junction inhibitor 2-aminoethoxy-diphenyl-borate protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes and c-jun N-terminal kinase activation.
-
The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury.
-
The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
-
The role of Smad3 in mediating mouse hepatic stellate cell activation.
-
The role of the c-Jun N-terminal kinases 1/2 and receptor-interacting protein kinase 3 in furosemide-induced liver injury.
-
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.
-
The β-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice.
-
Tools for causality assessment in drug-induced liver disease.
-
Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient.
-
Troglitazone-associated hepatotoxicity treated successfully with steroids.
-
Tuberculosis patient expenditure on drugs and tests in subsidised, public services in China: a descriptive study.
-
Ultrastructural alterations in liver of medaka (Oryzias latipes) exposed to diethylnitrosamine.
-
Value of liver biopsy in the diagnosis of drug-induced liver injury.
-
Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding.
-
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
-
Keywords of People